good scientific overview here: https://blogs.sciencemag.org/pipeline/archives/2020/09/09/serious-adverse-event-time
Transverse myelitis (TM), a rare neurological condition in which the spinal cord is inflamed, was observed in a patient.
The spinal cord inflammation seen in TM has been associated with various infections, immune system disorders, or damage to nerve fibers, by loss of myelin.
"...since vaccines are designed to be given exclusively to people who are not sick (a very unusual situation in drug development work!), the safety standards have to be very high. But the adverse events themselves (especially the serious ones) can be extremely rare, and the only way to get a statistical foothold on them is to have a very large controlled patient population under study. The Oxford/AstraZeneca trial is enrolling nearly 30,000 people, and the problem is that that may still not be enough for a definite answer on something like this.
bottom line: looking for such stuff is WHY we have clinical trials and why we take the time to look over all of the data with a fine tooth comb, rather than rushing to deliver a miracle late October surprise.
Transverse myelitis (TM), a rare neurological condition in which the spinal cord is inflamed, was observed in a patient.
The spinal cord inflammation seen in TM has been associated with various infections, immune system disorders, or damage to nerve fibers, by loss of myelin.
"...since vaccines are designed to be given exclusively to people who are not sick (a very unusual situation in drug development work!), the safety standards have to be very high. But the adverse events themselves (especially the serious ones) can be extremely rare, and the only way to get a statistical foothold on them is to have a very large controlled patient population under study. The Oxford/AstraZeneca trial is enrolling nearly 30,000 people, and the problem is that that may still not be enough for a definite answer on something like this.
bottom line: looking for such stuff is WHY we have clinical trials and why we take the time to look over all of the data with a fine tooth comb, rather than rushing to deliver a miracle late October surprise.